Business Wire

Upstream Bio to Present New Clinical Data from Phase 1 Study of UPB-101 at the American Thoracic Society (ATS) International Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Upstream Bio, a clinical-stage biotech company advancing new therapies to treat inflammation, today announced an upcoming poster presentation featuring new clinical ...
Nasdaq

Mustang Bio Announces FDA Orphan Drug Designation for MB-101 in Treatment of Recurrent Glioblastoma and High-Grade Astrocytomas

Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...